摘要
目的:观察多西他赛单药治疗老年中晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法:初诊、年龄在70～81岁之间的中晚期NSCLC患者42例,给予多西他赛75mg/m^2,第1天静滴,21d为一个周期,完成两个周期后评价疗效,有效及稳定病例完成4个周期,并至少随诊至疾病进展和患者死亡。结果:42例患者中,共40例可评价疗效,完全缓解(CR)1例,部分缓解(PR)9例,稳定(SD)13例,进展(PD)17例,总缓解率(CR+PR)为25.0%,疾病控制率(CR+PR+SD)为57.5%,中位无进展生存期(TTP)为4.2月,中位生存期为6.1月,1年生存率为35.8%。毒副反应主要以骨髓抑制为主。结论;多西他赛单药一线治疗老年中晚期非小细胞肺癌具有较好的疗效,患者的耐受性较好。
Objective:The aim of our study was to evaluate the clinical effects of docetaxel as single chemotherapy for elderly patients with advanced non-small-cell lung cancer(NSCLC).Methods:Forty-two elderly patients with advanced NSCLC who were chemotherapy-naive were enrolled in this study.Docetaxel at the doses of 75mg/m^2 was administrated intravenously every 21 days as a cycle,each patient received at least 2 cycles.All patients were followed up until disease progressed or patients died.Results:Among 42 patients,40 cases could be evaluated,1 case complete response(CR), 9 cases partial response(PR),13 cases stable disease(SD),17 cases progress disease(PD).The overall response rate (CR+PR) was 25.0%and disease control rate(CR+PR+SD) was 57.5%.The median time to progress(TTP) was 4.2 months,median survival time was 6.1 months and 1-year survival rate was 35.8%.The main toxicity was myelo-suppression. Conclusion:Single agent docetaxel for elderly patients with advanced NSCLC is an effective and well-tolerated chemotherapeutic approach with a low toxicity level.
